Protein kinases C: Potential targets for intervention in diabetic nephropathy

Current Opinion in Nephrology and Hypertension

Volumn 7, Issue 5, 1998, Pages 563-570

  Murphy, Madeline ^a   McGinty, Ann ^a   Godson, Catherine ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE C; PROTEIN KINASE INHIBITOR;

DIABETES MELLITUS; DIABETIC NEPHROPATHY; ENZYME ACTIVITY; HUMAN; INSULIN RESISTANCE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; ENZYME INHIBITORS; GENE THERAPY; HUMANS; ISOENZYMES; PROTEIN KINASE C;

EID: 0031686295     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199809000-00013     Document Type: Review

References (63)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-986.
2. Nishizuka Y. Intracellular signalling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992; 258:607-614.
3. Dekker LV, Palmer RH, Parker PJ. The protein kinase C and protein kinase C related gene families. Curr Opin Struct Biol 1995; 5:396-402.
4. Jaken S. Protein kinase C isozymes and substrates. Curr Opin Cell Biol 1996; 8:168-173.
5. Nishizuka Y. Protein kinase C and lipid signalling for sustained cellular responses. FASEB J 1995; 9:484-496.
6. Godson C, Masliah E, Balboa M, Ellisman MH, Insel PA. Isoform specific redistribution of protein kinase C in living cells. Biochim Biophys Acta 1996; 1313:63-71.
7. Newton AC. Regulation of protein kinase C. Curr Opin Cell Biol 1997; 9:161-167. An interesting review highlighting the contribution of the various regulatory domains of PKC to controlling its enzymatic activity.
8. Mochly-Rosen D. Compartmentalization of protein kinase by intracellular receptor proteins, a theme in signal transduction. Science 1995; 268:247-251.
9. Mochly-Rosen D, Gordon AS. Anchoring proteins for protein kinase C: a means for isozyme selectivity. FASEB J 1998; 12:35-42. This is an excellent state of the art review demonstrating the role of intracellular binding proteins as anchors for either activated or inactive PKC. The authors discuss the importance of these proteins in modulating thus controlling the biological activity of specific PKC isoforms.
10. Csukai M, Chen C-H, De Matteis MA, Mochly-Rosen D. The coatomer protein β'COOP: a selective RACK for epsilon PKC. J Biol Chem 1997; 272:29200-29206. This important paper describes the identification of a PKCε-specific RACK by expression cloning.
11. Ron D, Mochly-Rosen D. Agonists and antagonists of protein kinase C function, derived from its binding proteins. J Biol Chem 1994; 269:21398-21398.
12. House C, Kemp B. Protein kinase C contains a pseudosubstrate prototope in its regulatory domain. Science 1987; 238:1726-1728.
13. Johnson JA, Gray MO, Chen C-H, Mochly-Rosen D. A protein kinase C translocation inhibitor is an isozyme-selective antagonist of cardiac function. J Biol Chem 1996; 271:24962-24966.
14. Hundle B, McMahon T, Dadgar J, Chen C-H, Mochly-Rosen D, Messing R. An inhibitory fragment derived from ε-protein kinase C prevents the enhancement of nerve growth factor responses by ethanol and phorbol ester. J Biol Chem 1997; 272:1417-1420. This paper demonstrates the feasibility of using RACKs-derived peptide sequences to block translocation and hence activation of specific PKC isoforms in intact cells.
15. Klauck T, Faux M, Labudda K, Langenberg L, Jaken S, Scott J. Coordination of three signalling enzymes by AKAP79, a mammalian scaffold protein. Science 1996; 271:1589-1592.
16. Hofman J. The potential for isoenzyme-selective modulation of protein kinase C. FASEB J 1997; 11:649-669. This comprehensive review provides useful information on the relative specificity of PKC inhibitors targeted at different domains of the kinase.
17. Bleyer AJ, Fumo P, Snipes ER, Goldfarb S, Simmons DA, Ziyadeh FN. Polyol pathway mediates high glucose-induced collagen synthesis in proximal tubule. Kidney Int 1994; 45:659-666.
18. Williamson JR, Chang K, Frangos M, Hassan KS, Ido Y, Kawamura T, et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993; 42:801-813.
19. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318:1315-1321.
20. Craven PA, Davidson CM, DeRubertis FR. Increase in diacylglycerol mass in isolated glomeruli by glucose from de novo synthesis of glycerolipids. Diabetes 1990; 39:667-674.
21. King GL, Ishii H, Koya D. Diabetic vascular dysfunctions: a model of excessive activation of protein kinase C. Kidney Int 1997; 52 (Suppl 60):S77-S85. A useful review as it highlights the role of PKC in diabetic vascular dysfunction.
22. Ishii H, Koya D, King GL. Protein kinase C activation and its role in the development of vascular complications in diabetes. J Mol Med 1998; 76:21-31. This is an excellent, comprehensive and timely paper.
23. Ayo SH, Radnik R, Garoni JA, Troyer DA, Kreisberg JI. High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures. Am J Physiol 1991; 261:F571-F577.
24. Shiba T, Inoguchi T, Sportman JR, Heath W, Bursell S, King GL. Correlation of diacylglycerol and protein kinase C activity in rat retina to retinal circulation. Am J Physiol 1993; 265:E783-E793.
25. Xia P, Inoguchi T, Kern TS, Engerman RL, Oates PJ, King GL. Characterisation of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 1994; 43:1122-1129.
26. Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL. Preferential elevation of protein kinase C isoform βII and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 1992; 89:11059-11063.
27. Craven P, DeRubertis FR. Protein kinase C activation in glomeruli from streptozotocin diabetic rats. J Clin Invest 1989; 83:1667-1675.
28. Inoguchi T, Pu X, Kunisaki M, Higashi S, Feener EP, King GL. Insulin's effects on protein kinase C and diacylglycerol induced by diabetes and glucose in vascular tissues. Am J Physiol 1994; 267:E369-E379.
29. Heilig CW, Brosius FC, Henry DN. Glucose transporters of the glomerulus and the implications for diabetic nephropathy. Kidney Int 1997; 52 (Suppl 60):S91-S99. This report highlights the importance of glomerular glucose transporters in diabetic nephropathy. These are probably important mediators of PKC activity as de-novo 1,2-diacylglycerol synthesis is dependent on glucose availability.
30. Yasunari K, Kohno M, Kano H, Yokokawa K, Horio T, Yoshikawa J. Possible involvement of phospholipase D and protein kinase C in vascular growth induced by elevated glucose concentrations. Hypertension 1994; 28:159-168.
31. Kunisaki M, Bursell SE, Umeda F, Nawata H, King GL. Normalization of diacylglycerol-protein kinase C activation vitamin E in aorta of diabetic rats and cultured rat smooth muscle cells exposed to elevated glucose levels. Diabetes 1994; 43:1372-1377.
32. Morigi M, Angioletti S, Imberti B, Donadelli R, Miceheletti G, Figliuzzi M, et al. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in an NF-κB-dependent fashion. J Clin Invest 1998; 101:1905-1915.
33. Babazono T, Kapor-Drezgic J, Diugosz JA, Whiteside C. Altered expression and subcellular localization of diacylglycerol-sensitive protein kinase C isoforms in diabetic rat glomerular cells. Diabetes 1998; 47:668-676. This is an important paper as it demonstrates the independent modulation of PKC isoforms within different cell types in response to high glucose and to insulin.
34. Kikkawa M, Haneda M, Uzu T, Koya D, Sugimoto T, Shigeta Y. Translocation of protein kinase C α and ζ in rat glomerular mesangial cells cultured under high glucose conditions. Diabetologia 1994; 37:838-841.
35. Koya, D, Jirousek MR, Lin Y-W, Ishii H, Kuboki K, King GL. Characterization of protein kinase C β isoform activation on the gene expression of transforming growth factor-β, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 1996; 100:115-126. This is a very important paper, which expands on the data in Ref. 54. The authors show that in cultured mesangial cells glucose-induced biochemical abnormalities can be inhibited by LY333531. Furthermore, the treatment of diabetic rats with LY333531 inhibited increased mRNA for TGF-β1 and extracellular matrix proteins concomitant with the inhibition of elevated glomerular PKC activity.
36. Williams B, Schrier RW. Glucose-induced protein kinase C activity regulates arachidonic acid release and eicosanoid production by cultured glomerular mesangial cells. J Clin Invest 1993; 92:2889-2896.
37. 2. J Clin Invest 1995; 96:733-740.
38. Haneda M, Araki S-I, Togawa M, Sugimoto T, Isono M, Kikkawa R. Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions. Diabetes 1997; 46:847-853. This paper is important as it demonstrates that MAP kinase and MEK are chronically activated in the glomeruli from diabetic rats, which correlates with increased PKC activity.
39. 2 is phosphorylated and activated by MAP kinase. Cell 1993; 72:269-278.
40. Sharma K, Danoff TM, Depiero A, Ziyadeh FN. Enhanced expression of inducible nitric oxide synthase in murine macrophages and glomerular mesangial cells by elevated glucose levels: possible mediation via protein kinase C. Biochem Biophys Res Commun 1995; 207:80-88.
41. Aiello LP, Robinson GS, Lin Y-W, Nishio Y, King GL. Identification of multiple genes in bovine retinal pericytes altered by exposure to elevated levels of glucose by using mRNA differential display. Proc Natl Acad Sci USA 1994; 91:6231-6235.
42. Whiteside CI, Hurst RD, Stevanovic ZS. Calcium signaling and contractile response of diabetic glomerular mesangial cells. Kidney Int 1995: 48 (Suppl 51):S28-S33.
43. Young BA, Johnson RJ, Alpers CE, Eng E, Gordon K, Floege J, Couser WG. Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int 1995; 47:935-944.
44. Ziyadeh FN, Han DC. Involvement of transforming growth factor-β and its receptors in the pathogenesis of diabetic nephropathy. Kidney Int 199; 52 (Suppl 60):S7-S11. A timely review on the role of TGF-β in diabetic nephropathy.
45. Kim S-J, Denhez F, Kim K-Y, Holt JT, Sporn MB, Roberts AB. Activation of the second promoter of the transforming growth factor-β1 gene by transforming growth factor β-1 and phorbol ester occurs through the same target sequences. J Biol Chem 1989; 254:19373-19378.
46. Sharma K, Jin Y, Guo J, Ziyadeh FN. Neutralization of TGF-β by anti-TGF antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996; 45:522-530.
47. Okano R, Mita T, Matsui T. Characterization of a novel promoter structure and its transcriptional regulation of the murine laminin B1 gene. Biochim Biophys Acta 1992; 1132:3522-3527.
48. Dean DC, McQuillian JJ, Weintraub S. Serum stimulation of fibronectin gene expression appears to result from rapid serum-induced binding of nuclear proteins to a cAMP response element. J Biol Chem 1990; 265:3522-3527.
49. Willmer WA, Cosio FG. DNA binding of activator protein-1 is increased in human mesangial cells cultured in high glucose concentrations. Kidney Int 1998; 53:1172-1181. The authors demonstrate the importance of the post-translational modification of AP-1 in modulating its transactivating capacity.
50. Hempel A, Maasch C, Heintze U, Lindschau C, Dietz R, Luft FC, et al. High glucose concentrations increase endothelial cell permeability via activation of PKCα Circ Res 1997; 81:363-371. An interesting paper in which high glucose-induced alterations of endothelial cell permeability were attributed to PKCα on the basis of the inhibition of expression with antisense oligodeoxydenucleotide.
51. Aiello LP, Bursell S-E, Clermont A, Duh E, Ishii H, Takagai C, et al. Vascular endothelial growth-factor induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform selective inhibitor. Diabetes 1997; 46:1473-1480. This is an important paper showing that although VEGF activates multiple PKCs in the retina, specific inhibition of PKCβ is sufficient to inhibit VEGF-induced changes in intraocular permeability.
52. +-ATPase and Ca-ATP activity. In contrast, reduced PKC activity in the sciatic nerves was unchanged by LY 3333531.
53. Donnelly R, Qu X. Mechanisms of insulin resistance and new pharmacological approaches to metabolism and diabetic complications. Clin Exp Pharmacol Physiol 1998; 25:79-87. This is a timely review indicating the role of specific PKC isoforms regulating glucose transport, metabolism and insulin resistance.
54. Ishii H, Jirousek MR, Koya D, Takagai C,. Xia P, Clermont A, Bursell S-E, et al. Amelioration of vascular dysfunction in diabetic rats by an oral PKCβ inhibitor. Science 1996; 272:728-731.
55. Godson C, Bell KS, Insel PA. Inhibition of expression of protein kinase C α by antisense cDNA inhibits phorbol ester-mediated arachidonate release. J Biol Chem 1993; 268:11946-11950.
56. Branch AD. A good antisense molecule is hard to find. TIBS 1998; 23:45-50. A useful review on the challenges of developing antisense molecules as future therapeutics.
57. Dean N, McKay R, Miraglia L, Howard R, Cooper S, Giddings J, et al. Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of protein kinase C-α expression. Cancer Res 1996; 56:3499-3507
58. Kitamura M, Fine LG. Gene transfer into the kidney: promises and limitations. Kidney Int 1997; 52 (Suppl 60):S86-S90.
59. Akagi Y, Isaka Y, Arai M, Kaneko T, Takenaka T, Moriyama T, et al. Inhibition of transforming growth factor-β1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1996; 50:148-155.
60. Isaka Y, Brees DK, Ikegaya K, Kaneda Y, Imai E, Nobel NA, Border WA. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature Med 1996; 2:418-423.
61. Isaka Y, Akagaki Y, Ando Y, Imai E. Aplication of gene therapy to diabetic nephropathy. Kidney Int 1997; 52 (Suppl 60):S100-S103. This paper contains interesting data on the attenuation of diabetic nephropathy in streptozotocin-treated rats by intramuscular transfection of a chimeric TGF-β receptor.
62. Koya D, Lee I-K, Ishii H, Kanoh H, King GL. Prevention of glomerular dysfunction in diabetic rats by treatment with d-α-tocopherol. J Am Soc Nephrol 1997; 8:426-435. This paper shows that vitamin D prevents 1,2-diacylglycerol accumulation in the glomeruli of diabetic rats and normalizes renal function, which was associated with increased 1,2-diacylglycerol kinase activity, further supporting the importance of 1,2-diacylglycerol as a modulator of diabetic nephropathy by PKC activation.
63. Koya D, Haneda M, Kikkawa R, King GL. d-α-Tocopherol treatment prevents glomerular dysfunctions in diabetic rats through inhibition of protein kinase C-diacylglycerol pathway. BioFactors 1998; 7:69-76.